A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects With Previously Treated Hematological Cancers
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2017
At a glance
- Drugs CBLC 137 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Cleveland BioLabs; Incuron
- 17 Jan 2017 Status changed from not yet recruiting to recruiting.
- 11 Oct 2016 Status changed from planning to not yet recruiting.
- 09 Jan 2015 New trial record